UNSPSC 85662545: Supplement left hip tendon with autologous tissue substitute, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement left hip tendon with autologous tissue substitute, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0LUK47Z

UNSPSC 85662545, Supplement left hip tendon with autologous tissue substitute, percutaneous endoscopic approach, is a Commodity code that shows no relevant recent activity in state and local procurement. The code names a specific surgical procedure performed on a patient's hip using the patient's own tissue; however, the six recent opportunities posted in the source reflect administrative health services, medical benefit programs, occupational surveillance, pharmacy management, and temporary staffing — none of which involve performing or procuring this surgical procedure itself. State and local governments do not routinely solicit for specific orthopedic surgical procedures through RFP, RFQ, IFB, or ITB processes; such work is typically embedded within broader health system contracts or performed by employed clinical staff rather than procured as a distinct line item.

The mismatch between the code's clinical scope and the actual opportunities posted suggests the code is either unmatched to genuine state and local buying activity or has been misapplied to administrative or staffing solicitations that do not involve this procedure. No opportunities name hip tendon supplementation, autologous tissue grafting, or percutaneous endoscopic surgical services in their scope. Unless there is a specific procurement vehicle (such as a statewide health system group purchasing organization or a specialty surgical center lease) that regularly uses this code for procedure-specific contracting, pursuit of opportunities under this code is not advisable based on the current market signal.